blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4013460

EP4013460 - SMART PEPTIDES AND TRANSFORMABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  20.05.2022
Database last updated on 30.10.2024
FormerThe international publication has been made
Status updated on  19.02.2021
Most recent event   Tooltip28.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
[2022/25]
Inventor(s)01 / LAM, Kit S.
1524 Arena Drive
Davis, California 95618 / US
02 / ZHANG, Lu
2281 Hurley Way, Apartment 8
Sacramento, California 95825 / US
 [2022/25]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/25]
Application number, filing date20852074.214.08.2020
[2022/25]
WO2020US46495
Priority number, dateUS201962886698P14.08.2019         Original published format: US 201962886698 P
US201962886718P14.08.2019         Original published format: US 201962886718 P
[2022/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2021030743
Date:18.02.2021
Language:EN
[2021/07]
Type: A2 Application without search report 
No.:EP4013460
Date:22.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application.
[2022/25]
Search report(s)International search report - published on:US25.03.2021
(Supplementary) European search report - dispatched on:EP26.10.2023
ClassificationIPC:A61K49/00, A61K51/00, A61K47/62, A61P35/00
[2022/25]
CPC:
A61K49/0021 (EP); A61K49/0056 (EP,US); A61K47/54 (EP);
A61K47/546 (EP,US); A61K47/64 (EP,US); A61K47/6929 (EP,US);
A61K49/0036 (EP,US); A61K49/0093 (EP,US); A61P35/00 (EP,US);
C07K14/4711 (EP); C07K14/71 (EP); C07K16/32 (EP);
C07K17/00 (EP); A61K2039/54 (EP); A61K2039/55555 (EP);
A61K2039/572 (EP); B82Y5/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/25]
TitleGerman:INTELLIGENTE PEPTIDE UND TRANSFORMIERBARE NANOPARTIKEL ZUR KREBS-IMMUNTHERAPIE[2022/25]
English:SMART PEPTIDES AND TRANSFORMABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY[2022/25]
French:PEPTIDES INTELLIGENTS ET NANOPARTICULES TRANSFORMABLES POUR UNE IMMUNOTHÉRAPIE ANTICANCÉREUSE[2022/25]
Entry into regional phase02.03.2022National basic fee paid 
02.03.2022Search fee paid 
02.03.2022Designation fee(s) paid 
02.03.2022Examination fee paid 
Examination procedure02.03.2022Examination requested  [2022/25]
09.05.2024Amendment by applicant (claims and/or description)
09.05.2024Date on which the examining division has become responsible
Fees paidRenewal fee
29.08.2022Renewal fee patent year 03
28.08.2023Renewal fee patent year 04
27.08.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YA]US2014155577  (PARQUETTE JONATHAN R [US], et al) [Y] 1-3 * claims 1-21 * [A] 4-15;
 [YA]US9878052  (LI LIXIN [CN]) [Y] 1-3 * column 4, line 8 - line 57; claims 1-9 * [A] 4-15;
 [YA]  - WANG YIN ET AL, "Peptide-drug conjugates as effective prodrug strategies for targeted delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, (20160629), vol. 110, doi:10.1016/J.ADDR.2016.06.015, ISSN 0169-409X, pages 112 - 126, XP085062902 [Y] 1-3 * figure 3 * [A] 4-15

DOI:   http://dx.doi.org/10.1016/j.addr.2016.06.015
 [YA]  - MATTHEW J WEBBER ET AL, "Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 33, no. 28, doi:10.1016/J.BIOMATERIALS.2012.06.003, ISSN 0142-9612, (20120602), pages 6823 - 6832, (20120609), XP028428393 [Y] 1-3 * scheme 1; page 6824, column 1, line 29 - line 42 * [A] 4-15

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2012.06.003
 [YA]  - ACAR HANDAN ET AL, "Self-assembling peptide-based building blocks in medical applications", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, (20160814), vol. 110, doi:10.1016/J.ADDR.2016.08.006, ISSN 0169-409X, pages 65 - 79, XP085062906 [Y] 1-3 * page 70, column 1, line 24 - line 41; figure 8 * [A] 4-15

DOI:   http://dx.doi.org/10.1016/j.addr.2016.08.006
 [YA]  - LI SHUKUN ET AL, "Nanodrugs based on peptide-modulated self-assembly: Design, delivery and tumor therapy", CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, GB, (20180501), vol. 35, doi:10.1016/j.cocis.2017.12.004, ISSN 1359-0294, pages 17 - 25, XP055805394 [Y] 1-3 * page 10, line 2 - page 11, line 12 * [A] 4-15

DOI:   http://dx.doi.org/10.1016/j.cocis.2017.12.004
 [YA]  - MATSON JOHN B. ET AL, "Nanostructure-templated control of drug release from peptide amphiphile nanofiber gels", SOFT MATTER, GB, (20120101), vol. 8, no. 13, doi:10.1039/c2sm07420f, ISSN 1744-683X, page 3586, XP093092527 [Y] 1-3 * scheme 1;; figure 12 * [A] 4-15

DOI:   http://dx.doi.org/10.1039/c2sm07420f
International search[A]US9579400  (LAM KIT S [US], et al) [A] 1-3; 35-37* ENTIRE DOCUMENT *;
 [YA]  - THOMAS et al., "Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates", Bioorg. Med. Chem. Lett., (20080000), vol. 18, doi:10.1016/j.bmcl.2008.09.078, pages 5785 - 5788, XP025562046 [Y] 1-3 * . pg. 5786, Figure 1, Structure 2 * [A] 35-37

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.09.078
 [YA]  - WANG et al., "Peptide-drug conjugates as effective prodrug strategies for targeted delivery", Advanced Drug Delivery Reviews, (20170000), vol. 110, no. 111, doi:10.1016/j.addr.2016.06.015, pages 112 - 126, XP085062902 [Y] 1-3 * . pg. 120, Figure 6 * [A] 35-37

DOI:   http://dx.doi.org/10.1016/j.addr.2016.06.015
 [A]  - LUO Yan, Wu Hao, Feng Caihong, Xiao Kai, Yang Xixiao, Liu Qiangqiang, Lin Tzu-Yin, Zhang Hongyong, Walton Jeffrey H., Ajena Yousif, Hu Yide, Lam Kit S., Li Yuanpei, ""One-Pot" Fabrication of Highly Versatile and Biocompatible Poly(vinyl alcohol)- porphyrin-based Nanotheranostics", Theranostics, (20170000), vol. 7, no. 16, doi:10.7150/thno.20190, pages 3901 - 3914, XP055805389 [A] 35-37 * . pg. 3906, Figure 1A *

DOI:   http://dx.doi.org/10.7150/thno.20190
 [A]  - LI Shukun, Xing Ruirui, Chang Rui, Zou Qianli, Yan Xuehai, "Nanodrugs based on peptide-modulated self-assembly: Design, delivery and tumor therapy", Current Opinion in Colloid and Interface Science, (20180500), vol. 35, doi:10.1016/j.cocis.2017.12.004, pages 17 - 25, XP055805394 [A] 35-37 * . pg. 18, Figure 1 *

DOI:   http://dx.doi.org/10.1016/j.cocis.2017.12.004
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.